Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TherapeuticsMD, Inc. Director's Dealing 2023

May 4, 2023

35134_dirs_2023-05-04_02d3240c-b00b-4dc6-aaeb-5c3a93f0d3a2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2023-04-12

Reporting Person: Walker Marlan D (Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-04-26 Common Stock M 1010 $0.00 Acquired 14041 Direct
2023-04-26 Common Stock M 1734 $0.00 Acquired 12307 Direct
2023-04-26 Common Stock S 692 $3.6381 Disposed 11615 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-04-26 Restricted Stock Units $0.00 M 1010 Disposed Common Stock (1010) Direct
2023-04-26 Restricted Stock Units $0.00 M 1734 Disposed Common Stock (1734) Direct

Footnotes

F1: The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date. The restricted stock units settled on April 26, 2023.

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023.

F4: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.